BioNTech to Hold Webcast to Present Early Positive Data from Ongoing Phase 1/2 Study of mRNA-based Vaccine Candidate Against SARS-CoV-2

Rhea-AI Summary

BioNTech (Nasdaq: BNTX) announced a conference call on July 1, 2020, at 11:00 a.m. EDT to discuss preliminary data from its ongoing Phase 1/2 trial of an mRNA-based vaccine against SARS-CoV-2. The firm continues to leverage its expertise in mRNA vaccine development and manufacturing to advance multiple vaccine candidates for infectious diseases and an extensive oncology pipeline. The call can be accessed via phone or webcast, with a replay available for 30 days post-event.

Positive

• Ongoing Phase 1/2 trial for mRNA vaccine against SARS-CoV-2.
• Strong expertise in mRNA vaccine development.
• Diverse pipeline including multiple candidates for infectious diseases and oncology.

Negative

• None.

MAINZ, Germany, July 01, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) will host a conference call and webcast today, July 1^st, 2020 at 11:00 a.m. EDT (5:00 p.m. CET) to discuss the preliminary data announced this morning from the ongoing Phase 1/2 trial of its mRNA-based vaccine program against SARS-CoV-2.

To participate in the conference call, please dial the following numbers 10-15 minutes prior to the start of the call and provide the Conference ID: 7176269.

100%; border-collapse:collapse !important;">

25%; width:25%; min-width:25%;">United States international:	75%; width:75%; min-width:75%;">+1 646 741 3167
United States domestic (toll-free):	+1 877 870 9135
Germany:	+49 692 2222 625

Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page of the Investor Relations section of the Company’s website at https://biontech.de/. A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company’s website for 30 days following the call.

About BioNTech

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline.

Contact

Investor Relations
Sylke Maas, Ph.D.
VP Investor Relations & Business Strategy
Tel: +49 (0)6131 9084 1074
E-mail: Investors@biontech.de

Media Relations
Jasmina Alatovic
Senior Manager Global External Communications
Tel: +49 (0)6131 9084 1513 or +49 (0)151 1978 1385
E-mail: Media@biontech.de

FAQ

What is the purpose of BioNTech's Phase 1/2 trial?

The trial aims to evaluate the efficacy and safety of an mRNA-based vaccine against SARS-CoV-2.

When will BioNTech discuss the Phase 1/2 trial results?

BioNTech will discuss the results during a conference call on July 1, 2020, at 11:00 a.m. EDT.

How can I access BioNTech's conference call on the trial data?

Participants can call specific numbers provided in the press release or access the webcast via their Investor Relations website.

What is BioNTech's stock symbol?

BioNTech's stock symbol is BNTX, and it is traded on Nasdaq.

What type of vaccines is BioNTech developing?

BioNTech is developing mRNA-based vaccine candidates for infectious diseases and has a diverse oncology pipeline.